SecBot SecBot
3 ·Filed Apr 30, 2026

COAG

Hemab Therapeutics Holdings, Inc.
NEUTRAL
Impact 3/10
Horizonimmediate Processed6mo ago SEC0001388325-26-000019
Form 3, initial insider ownership statement
Actionable Insight • Neutral

This is a standard Form 3 filing with no trading activity or change in position. Monitor for subsequent Form 4 filings if Novo Holdings buys or sells shares post-IPO, which could signal conviction changes. The large convertible stake indicates Novo Holdings is a key insider with potential influence on corporate governance.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$34.00
T+0 close · Apr 30, 2026 · via day close
Latest settled
+39.00%
T+60 · $47.26
Vs SPY
+35.93%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 1 $34.00entry
  2. T+1 · 7mo ago −25.47%α −25.13% · $25.34
  3. T+5 · 6mo ago −26.12%α −28.46% · $25.12
  4. T+20 · 6mo ago −20.21%α −25.47% · $27.13
  5. T+60 · 4mo ago +39.00%α +35.93% · $47.26

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Novo Holdings A/S filed a Form 3 initial statement of beneficial ownership, disclosing holdings in Hemab Therapeutics (COAG) ahead of its IPO. The filing shows Novo Holdings beneficially owns 513,546 shares of Common Stock and convertible preferred shares (Series Seed, A, B, C) that convert to Common Stock on a 22-for-1 basis at IPO closing, totaling approximately 4,177,550 common-equivalent shares. This signals Novo Holdings' significant pre-IPO stake but provides no new financial data or trading activity.

Key Facts

  • Novo Holdings A/S filed Form 3 as an initial beneficial ownership report for Hemab Therapeutics Holdings, Inc. (COAG).
  • Novo Holdings directly owns 513,546 shares of Common Stock.
  • Novo Holdings also holds Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock, each convertible into Common Stock on a 22-for-1 basis immediately prior to the IPO closing.
  • The convertible preferred shares represent approximately 3,664,004 common-equivalent shares (1581052 + 1366662 + 719290 + 0 for Series Seed? Actually Series Seed amount not given in the XML snippet, but the total from the listed preferred series is 1581052 + 1366662 + 719290 = 3,664,004). Combined with the 513,546 common shares, total beneficial ownership is approximately 4,177,550 common-equivalent shares.
  • The filing is dated April 30, 2026, and is a routine initial ownership disclosure required under Section 16(a) of the Securities Exchange Act of 1934.
  • No transactions or changes in ownership are reported; this is a snapshot of holdings as of the filing date.

Financial Impact

No financial impact; the filing is a routine disclosure of pre-IPO beneficial ownership by a major shareholder.

Risk Factors

  • No material risks identified from this filing alone; it is a routine disclosure.

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
3 Filing (Primary)0001388325-26-000019
Document: 0001388325-26-000019-index.html0001388325-26-000019
Document: 0001388325-26-000019.txt0001388325-26-000019

Track record

19 reports on COAG

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 10, 20266d ago Press Release Neutral 4/10 Entry $38.77 Now $39.06 +0.75% settles Nov 17
  2. Nov 9, 20267d ago Press Release Bullish 6/10 Entry $42.81 to $39.06 Now $39.06 −8.76% ▼ −8.77% −7.08% vs SPY
  3. Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $49.02 to $40.86 Now $39.06 −20.32% ▼ −16.65% −19.24% vs SPY
  4. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $45.09 to $39.33 Now $39.06 −13.37% ▼ −12.77% −11.86% vs SPY
  5. Sep 25, 20267w ago 3 Neutral 2/10 Entry $33.12 to $30.59 Now $39.06 +17.93% ▼ −7.64% −8.84% vs SPY
  6. Sep 17, 20268w ago Press Release Neutral 4/10 Entry $41.22 to $35.72 Now $39.06 −5.24% ▼ −13.34% −14.19% vs SPY
  7. Aug 11, 202613w ago 8-K Bullish 7/10 Entry $49.87 to $52.44 Now $39.06 −21.68% ▲ +5.15% +5.56% vs SPY
  8. Jun 17, 202621w ago Insider Buy Neutral 2/10 Entry $29.24 to $27.72 Now $39.06 +33.58% ▼ −5.20% −3.53% vs SPY
  9. May 21, 202625w ago Press Release Neutral 5/10 Entry $26.30 to $28.50 Now $39.06 +48.52% ▲ +8.37% +6.52% vs SPY
  10. May 4, 202628w ago 8-K Neutral 4/10 Entry $25.00 to $25.90 Now $39.06 +56.24% ▲ +3.60% +1.62% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 8h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 30, 2026